Intravitreal bevacizumab treatment for neovascular glaucoma

Histopathological analysis of trabeculectomy specimens

Noriko Yoshida, Toshio Hisatomi, Yasuhiro Ikeda, Ri Ichiro Kohno, yusuke murakami, Hiroyuki Imaki, Akifumi Ueno, Kimihiko Fujisawa, Tatsuro Ishibashi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.

Original languageEnglish
Pages (from-to)1547-1552
Number of pages6
JournalGraefe's Archive for Clinical and Experimental Ophthalmology
Volume249
Issue number10
DOIs
Publication statusPublished - Oct 1 2011

Fingerprint

Neovascular Glaucoma
Trabeculectomy
Therapeutics
Diabetic Retinopathy
Electron Microscopy
Endothelial Cells
Off-Label Use
Trabecular Meshwork
Antibodies, Monoclonal, Humanized
Bevacizumab
Light
Temazepam
Capillary Permeability
Fibrin
Vascular Endothelial Growth Factor A
Blood Vessels
Microscopy
Edema
Histology
Protein Isoforms

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Intravitreal bevacizumab treatment for neovascular glaucoma : Histopathological analysis of trabeculectomy specimens. / Yoshida, Noriko; Hisatomi, Toshio; Ikeda, Yasuhiro; Kohno, Ri Ichiro; murakami, yusuke; Imaki, Hiroyuki; Ueno, Akifumi; Fujisawa, Kimihiko; Ishibashi, Tatsuro.

In: Graefe's Archive for Clinical and Experimental Ophthalmology, Vol. 249, No. 10, 01.10.2011, p. 1547-1552.

Research output: Contribution to journalArticle

Yoshida, Noriko ; Hisatomi, Toshio ; Ikeda, Yasuhiro ; Kohno, Ri Ichiro ; murakami, yusuke ; Imaki, Hiroyuki ; Ueno, Akifumi ; Fujisawa, Kimihiko ; Ishibashi, Tatsuro. / Intravitreal bevacizumab treatment for neovascular glaucoma : Histopathological analysis of trabeculectomy specimens. In: Graefe's Archive for Clinical and Experimental Ophthalmology. 2011 ; Vol. 249, No. 10. pp. 1547-1552.
@article{86785ab204044050b8eba35759f2982e,
title = "Intravitreal bevacizumab treatment for neovascular glaucoma: Histopathological analysis of trabeculectomy specimens",
abstract = "Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.",
author = "Noriko Yoshida and Toshio Hisatomi and Yasuhiro Ikeda and Kohno, {Ri Ichiro} and yusuke murakami and Hiroyuki Imaki and Akifumi Ueno and Kimihiko Fujisawa and Tatsuro Ishibashi",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s00417-011-1761-2",
language = "English",
volume = "249",
pages = "1547--1552",
journal = "Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie",
issn = "0065-6100",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Intravitreal bevacizumab treatment for neovascular glaucoma

T2 - Histopathological analysis of trabeculectomy specimens

AU - Yoshida, Noriko

AU - Hisatomi, Toshio

AU - Ikeda, Yasuhiro

AU - Kohno, Ri Ichiro

AU - murakami, yusuke

AU - Imaki, Hiroyuki

AU - Ueno, Akifumi

AU - Fujisawa, Kimihiko

AU - Ishibashi, Tatsuro

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.

AB - Background: Neovascular glaucoma (NVG) is a serious complication for patients with proliferative diabetic retinopathy (PDR). Bevacizumab is a full-length humanized monoclonal antibody that binds all isoforms of vascular endothelial growth factor (VEGF). Recently, encouraging results regarding the off-label use of intravitreal bevacizumab (IVB) for the treatment of NVG have been reported. We evaluated the histology of bevacizumab-treated trabeculectomy specimens to clarify IVB's biological effects on angle neovascularization. Methods: We retrospectively reviewed the charts of a consecutive series of 15 eyes of 13 patients who underwent trabeculectomy to treat NVG caused by PDR. In ten eyes of eight patients, 1.25 mg bevacizumab was injected intravitreally via the pars plana. Using light or electron microscopy, the surgically excised trabecular tissue was compared to that without IVB. Results: Light microscopy revealed decreased edema, fibrin deposition, inflammation and vascular congestion in the trabecular meshwork in specimens with IVB compared to those without IVB. Electron microscopy revealed endothelial cell degeneration in the bevacizumab-treated specimens. Conclusions: The biological effects on angle neovascularization after IVB may involve reduced vascular permeability, decreased inflammatory reaction, loss of vascular function, and endothelial cell degeneration.

UR - http://www.scopus.com/inward/record.url?scp=80755155795&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755155795&partnerID=8YFLogxK

U2 - 10.1007/s00417-011-1761-2

DO - 10.1007/s00417-011-1761-2

M3 - Article

VL - 249

SP - 1547

EP - 1552

JO - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

JF - Albrecht von Graefes Archiv für Klinische und Experimentelle Ophthalmologie

SN - 0065-6100

IS - 10

ER -